Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/278459 
Year of Publication: 
2023
Series/Report no.: 
Research Paper No. 176
Publisher: 
South Centre, Geneva
Abstract: 
In theory, the WHO is the coordinating agency for global health, and large private and public actors claim the relevance and central role of this UN agency. In practice, paradoxically, the money for health goes largely to other institutions and not to the WHO, or even new institutions or mechanisms are created where new funds are channeled (GAVI, Global Fund, Act-A, CEPI, COVAX, etc.) These institutions or mechanisms are, in most cases, public-private partnerships where the pharmaceutical industry is present. Official Development Assistance is important but represents only 1 per cent of what developing countries spend on health. What is actually spent to promote global health and where this money goes is the subject of this paper. One of the questions we must ask ourselves after the experience with COVID-19 is how will we preserve the global public interest by creating common public goods and protecting human rights in the prevention, preparedness and response to present and future pandemics.
Subjects: 
Access to Medicines
Coalition for Epidemic Preparedness Innovations (CEPI)
COVID-19
COVID-19 Vaccines Global Access (COVAX)
GAVI the Vaccine Alliance
Global Health
Global Public Good
Health
Human Rights
Medicines Patent Pool (MPP)
Official Development Assistance (ODA)
Pan American Health Organization (PAHO)
Pandemic
Pandemic Preparedness and Response
Pharmaceutical Industry
Public Interests
Public-Private Partnerships (PPPs)
The Access to COVID-19 Tools (ACT) Accelerator
The Global Fund
The Pandemic Fund
UN Global Compact
UNAIDS
Unitaid
WHO Foundation
WHO Sustainable Financing Working Group
World Health Organization (WHO)
Document Type: 
Research Report
Appears in Collections:

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.